fbpx Skip to main content


Commitment to Immunodermatology & Rheumatology Newsroom

Our Commitment to
Immunodermatology & Rheumatology
Our Commitment to
Immunodermatology & Rheumatology

Welcome to the Janssen Immunology Immunodermatology & Rheumatology Newsroom! Below, please find the latest data, content, meeting news, social feeds, and leadership messages about our progress and commitment to developing innovative medicines for diseases like psoriasis (PsO), psoriatic arthritis (PsA), atopic dermatitis (AD) and hidradenitis suppurativa (HS).


Dear All,

At Janssen Immunology, we remain steadfast in our commitment to address unmet need, uncover novel treatment approaches, and work collaboratively to deliver transformational therapies for patients living with chronic immune-mediated diseases. We understand that significant unmet need remains in many immune-mediated diseases, and that many patients around the world are struggling to find the right treatment, maintain symptom relief, and achieve remission. These patients are the motivating force that drives us to continue to pioneer research and achieve our vision to restore health for all patients with immune-mediated diseases.

Terence Rooney, M.D.
Disease Area Leader
Rheumatology and Maternal-Fetal Immunology
View Terence's profile

Lloyd Miller, M.D., Ph.D.
Disease Area Leader
View Lloyd's profile

June Lanoue
Disease Area Commercial Leader
Rheumatology & Dermatology
View June's profile








About Psoriasis

Psoriasis (PsO) is an immune-mediated disease resulting in an overproduction of skin cells, which causes raised, red, scaly plaques that may be itchy or painful.1 It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease.2 Nearly one-quarter of all people with psoriasis have cases that are considered moderate to severe.2 Living with psoriasis can be a challenge and impact life beyond a person’s physical health, including emotional health, relationships, and handling the stressors of life.3 Psoriasis is associated with multiple comorbidities, including psoriatic arthritis, metabolic syndrome, cardiovascular diseases, psychological disorders, inflammatory bowel disease, and additional immune-mediated diseases.4

About Psoriatic Arthritis

Psoriatic Arthritis (PsA) is a chronic, heterogeneous, immune-mediated inflammatory disease—people living with PsA can exhibit peripheral joint inflammation, enthesitis (pain where the bone, tendon and ligament meet), dactylitis (severe inflammation of the finger and toe joints), axial disease, and the skin lesions associated with psoriasis (PsO).5,6,7 In addition, in patients with PsA, comorbidities such as obesity, cardiovascular diseases, anxiety and depression are often present.8 Studies show up to 30 percent of people with PsO also develop PsA.9 The disease causes pain, stiffness and swelling in and around the joints; it commonly appears between the ages of 30 and 50, but can develop at any time.9 Nearly half of patients with PsA experience moderate fatigue and about 30 percent suffer from severe fatigue as measured by the modified fatigue severity scale.10 Although the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in disease onset.11

About Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic disease characterized by swollen, painful lesions, occurring in the armpit (axillae), groin, anal, and breast regions of men and women.12 This progressive disease occurs due to obstruction of hair follicles and secondary infection and sometimes inflammation of certain sweat glands (apocrine glands).12 Healing of affected areas is typically associated with progressive scarring (fibrosis).12 Formation of chronic epithelialized, sometimes interconnected, sinus tracts occur in severe disease.12 This often leads to the entrapment of perspiration and bacteria in the surrounding tissue, which causes the inflammation and infection.12 HS can be extremely painful and debilitating but is rarely life threatening; only occurring when the bacteria infection leads to an overwhelming systemic infection in an individual with a weakened immune system.11 Although the exact cause of HS is unknown, the condition likely results from a combination of genetic and environmental factors.12

About Atopic Dermatitis

Atopic dermatitis (AD), sometimes referred to as eczema, is a chronic skin disorder affecting more than 9.6 million children and 16.5 million adults in the United States. AD is characterized by an overactive immune system that causes damage to the skin barrier, leaving it dry, itchy, and rashes. AD may come and go throughout life and is considered a severe condition. The condition can cause poor quality of life by interrupting sleep due to itching and/or painful skin, and by impacting the ability to interact with family and friends.13

Driven by a relentless dissatisfaction with patients' remission, we will redefine treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients with autoimmune disease.

Learn more:

Follow Follow Janssen Global on Instagram, LinkedIn and Twitter.


1 National Psoriasis Foundation. About Psoriasis. https://www.psoriasis.org/about-psoriasis. Accessed March 2021.
2 National Psoriasis Foundation. Statistics. https://www.psoriasis.org/content/statistics. Accessed March 2021.
3 National Psoriasis Foundation. Life with Psoriasis. https://www.psoriasis.org/life-with-psoriasis/. Accessed March 2021.
4 Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9-20. doi:10.1590/abd1806-4841.20153038
5 Donvito, T. (2019, August 26). What Is Enthesitis? The Painful Arthritis Symptom You Should Know About. CreakyJoints. https://creakyjoints.org/symptoms/what-is-enthesitis/#:%7E:text=%E2%80%9CEnthesitis%20is%20inflammation%20of%20the,is%20susceptible%20to%20this%20problem
6 Donvito, T. (2019a, July 10). What Is Dactylitis? The ‘Sausage Finger’ Swelling You Should Know About. CreakyJoints. https://creakyjoints.org/symptoms/what-is-dactylitis/
7 Belasco, J., & Wei, N. (2019). Psoriatic Arthritis: What is Happening at the Joint? Rheumatology and Therapy, 6(3), 305–315. https://doi.org/10.1007/s40744-019-0159-1
8 Haddad A and Zisman D. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med J 2017;8(1):e0004.
9 Psoriatic Arthritis: Causes, Symptoms and Treatment. National Psoriasis Foundation. Retrieved February 22, 2021, from https://www.psoriasis.org/about-psoriatic-arthritis/
10 Husted, J. A., Tom, B. D., Schentag, C. T., Farewell, V. T., & Gladman, D. D. (2008). Occurrence and correlates of fatigue in psoriatic arthritis. Annals of the Rheumatic Diseases, 68(10), 1553–1558. https://doi.org/10.1136/ard.2008.098202
11 Cassell, S., & Kavanaugh, A. (2005, September 2). Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment. Journal of Immune Based Therapies and Vaccines. https://jibtherapies.biomedcentral.com/articles/10.1186/1476-8518-3-6
12 National Organization for Rare Disorders. Hidradenitis Suppurativa. https://rarediseases.org/rare-diseases/hidradenitis-suppurativa/. Accessed March 17, 2021.
13 National Eczema Association. Atopic Dermatitis. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/. Accessed on March 17, 2021